Overview / Abstract: |
Target Audience Activity Overview Various pharmacological therapeutic targets are emerging based on the evolving understanding of the autoimmune pathogenesis of the progression of IgAN, which involves the immune response, mucosal immunity, renal inflammation, complement activation, and autophagy. In this online activity, expert faculty provide information to help health care providers stay up to date on recent findings regarding the pathophysiology of IgAN, and the efficacy and safety profiles of available and emerging agents. Learning Objectives |
Expiration |
Jan 31, 2024 |
Discipline(s) |
Physician CME |
Format |
Online |
Credits / Hours |
1.5 |
Accreditation |
ACCME, ACPE |
Presenters / Authors / Faculty |
Richard Lafayette, MD, FACP |
Sponsors / Supporters / Grant Providers |
Travere Therapeutics |
Keywords / Search Terms |
Relias LLC Relias, Free CME, IgAN Free CE CME |